28657-39-8Relevant articles and documents
A new two-step procedure for functionalized-3(2H)-pyridazinones through homolytic substitution of 3-chloropyridazines
Dal Piaz,Giovannoni,Ciciani
, p. 3903 - 3906 (1993)
The homolytic substitution of protonated 3-chloro-6-methylpyridazine 1a, followed by hydrolysis with AcOH affords 4- or 4,5-functionalized pyridazinones 3a-c. Less reactivity is found for 3-chloro-6-phenylpyridazine 1b. Hypotheses about these different behaviour patterns are proposed and discussed.
FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS
-
Page/Page column 26-27, (2010/01/31)
The invention relates to chemical compounds, compositions and methods of making and using the same. In particular, the invention provides selected pyridazine compounds of the formula I are independently hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, sulfate, sulfenyl, sulfinyl, sulfonyl, sulfonate, sulfoxide, silyl, silyloxy, silylalkyl, silylthio, ═O, ═S, phosphonate, ureido, carboxyl, carbonyl, carbamoyl, or carboxamide; and X is optionally substituted pyrimidinyl or pyridazinyl, an isomer, a pharmaceutically acceptable salt, or derivative thereof. The invention additional relates to compositions comprising the compounds, and methods of using the compounds and compositions for modulation of cellular pathways, for treatment or prevention of inflammatory diseases, for research, drug screening, and therapeutic applications.
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits
Hu, Wenhui,Ralay Ranaivo, Hantamalala,Roy, Saktimayee M.,Behanna, Heather A.,Wing, Laura K.,Munoz, Lenka,Guo, Ling,Van Eldik, Linda J.,Watterson, D. Martin
, p. 414 - 418 (2007/10/03)
We report the development of a novel, aqueous-soluble, safe, small molecule, experimental therapeutic that suppresses injury-induced, proinflammatory cytokine increases in the brain, with resultant attenuation of synaptic protein biomarker loss and improvement in hippocampus-dependent behavioral deficits. A GMP production scheme for the active pharmaceutical ingredient, compound 17, is presented. The development and large-scale availability of this novel compound allow exploration of new, potentially disease-modifying, therapeutic approaches to CNS disorders.